The Global T-cell Lymphoma market size was accounted at USD 1.44 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 8.40% from 2022 to 2030. T-cell lymphoma is a rare type of cancerous lymphoma that begins in white blood cells (T cells). Lymphoma arises from the uncontrolled growth of mature T cells and can become cancerous. It can cause skin redness, scaly round patches on the skin, and skin tumors.
Several factors driving the growth of the T-cell Lymphoma Market include the rising lymphoma cancer cases, increasing technological advances in therapy techniques, increasing T-cell lymphoma-specific therapies, and increasing autoimmune disorders. Moreover, spreading awareness regarding the benefits of T-cell lymphoma therapeutics, surging demand for cost-efficient cancer treatments and boosting government funding for the R&D of innovative cancer therapies are further expected to deliver considerable market growth during the forecast period. According to Leukemia & Lymphoma Society 2020, around 85,720 new lymphoma cases were diagnosed in the United States in 2020. Additionally, the newly reported lymphoma cases include 8,480 cases of Hodgkin (HL) and 77,240 cases of Non-Hodgkin (NHL) Lymphoma, thereby upsurging the demand for this market.
However, the high cost of T-cell Lymphoma therapies, complicated production methods, and side effects of these therapies may restrict the market growth in the upcoming years.
The T-cell Lymphoma Market is classified based on lymphoma type, therapy, and region. By lymphoma type, the market is segmented into peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. Peripheral T-cell lymphoma is further divided into cutaneous T-cell lymphoma, anaplastic large cell lymphoma, angio-immuno-blastic T-cell lymphoma, and others (intestinal T-cell lymphoma, follicular T-cell lymphoma). By therapy, the market is grouped into radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others (antiviral treatment, etc.). The chemotherapy segment is expected to lead this market during the forecast years due to its increasing use for cancer treatments. Regionally, the market is segregated across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is anticipated to dominate the T-cell lymphoma market over the forecast period (2020-2030), owing to the increasing R&D expenditure and rising incidences of lymphoma in this region.
Few key players operating in the T-cell lymphoma market are 4SC AG, Acrotech Biopharma, Affimed, Bausch Health Companies Inc., Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Elorac, F. Hoffmann-La Roche Ltd, Genmab A/S, Genor Biopharma, GlaxoSmithKline plc., Innate Pharma, Johnson and Johnson Private Limited, Kyowa Kirin Co., Ltd., Merck and Co. Inc., Novartis AG, Pfizer, Roche, Seagen Inc., Secura Bio, Shanghai Junshi Bio, SHIONOGI & Co., Ltd., Solasia, Spectrum Pharmaceuticals Inc., Takeda, Viracta, and Other Prominent Players.
